Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...
Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by ...
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...
A new study from Edith Cowan University (ECU) in Australia suggests that exercise may help reduce the risk of breast cancer ...
In our modern world, chemicals play an essential role in creating products that make daily life more convenient. However, ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.
Assessment of PSA level for three months after radical prostatectomy for prostate cancer may minimize overtreatment.
AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback